Exploratory development of PCR-fluorescent probes in rapid detection of mutations associated with extensively drug-resistant tuberculosis

This study aims to evaluate the clinical value of PCR-fluorescent probes for detecting mutation gene associated with extensively drug-resistant tuberculosis (XDR-TB). The molecular species identification 900 sputum specimens was performed using polymerase chain reaction (PCR)–fluorescent probe. mutations drug resistance genes rpoB, katG, inhA, embB, rpsL, rrs, and gyrA were detected. conventional susceptibility testing (DST) PCR-directed sequencing (PCR-DS) carried out as control. DST demonstrated that there 501 strains rifampicin resistance, 451 isoniazid 293 quinolone 425 streptomycin 235 ethambutol 204 amikacin resistance. Furthermore, 427 (47.44%) or 146 (16.22%) MDR-TB XDR-TB, respectively. detected in 751 TB patients by probe method, rate 751/900 (83.44%). No mutant other 149 patients. Compared DST, rates katG/inhA, six drugs higher than 88%; five 90% except SM (88.11%). MDR XDR types found 398 (42.22%) 137 (15.22%) samples. PCR-DS also employed confirmed method accordance 100%. is rapid straightforward XDR-TB genotypes worthy being applied hospitals.